156 related articles for article (PubMed ID: 21233249)
41. The role of neoadjuvant chemotherapy in ovarian cancer.
Elies A; Rivière S; Pouget N; Becette V; Dubot C; Donnadieu A; Rouzier R; Bonneau C
Expert Rev Anticancer Ther; 2018 Jun; 18(6):555-566. PubMed ID: 29633903
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
Taşkın S; Güngör M; Ortaç F; Öztuna D
Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
[TBL] [Abstract][Full Text] [Related]
43. The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
Van Gorp T; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
Minerva Ginecol; 2006 Oct; 58(5):393-403. PubMed ID: 17006426
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
45. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
46. Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging.
Kumar L; Pramanik R; Kumar S; Bhatla N; Malik S
Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):790-801. PubMed ID: 25840650
[TBL] [Abstract][Full Text] [Related]
47. A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy.
Eoh KJ; Yoon JW; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
BMC Cancer; 2017 Jul; 17(1):481. PubMed ID: 28701190
[TBL] [Abstract][Full Text] [Related]
48. [Neoadjuvant chemotherapy in the treatment of ovarian cancer].
Lehoczky O
Orv Hetil; 2005 Sep; 146(38):1951-5. PubMed ID: 16238247
[TBL] [Abstract][Full Text] [Related]
49. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.
Leiserowitz GS; Lin JF; Tergas AI; Cliby WA; Bristow RE
Int J Gynecol Cancer; 2017 May; 27(4):675-683. PubMed ID: 28328580
[TBL] [Abstract][Full Text] [Related]
50. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
Nicklin JL; McGrath S; Tripcony L; Garrett A; Land R; Tang A; Perrin L; Chetty N; Jagasia N; Crandon AJ; Nascimento M; Walker G; Sanday K; Obermair A
Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):651-658. PubMed ID: 28718942
[TBL] [Abstract][Full Text] [Related]
51. Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer.
Iura A; Takita M; Kawano A; Imai K; Konnai K; Onose R; Kato H
J Gynecol Oncol; 2018 Sep; 29(5):e70. PubMed ID: 30022634
[TBL] [Abstract][Full Text] [Related]
52. Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future?
Schorge JO; Bradford LS; del Carmen MG
Clin Adv Hematol Oncol; 2011 Dec; 9(12):912-8. PubMed ID: 22252659
[TBL] [Abstract][Full Text] [Related]
53. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach.
Feuer GA; Lakhi N; Barker J; Salmieri S; Burrell M
Gynecol Oncol; 2013 Dec; 131(3):520-4. PubMed ID: 24080421
[TBL] [Abstract][Full Text] [Related]
54. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages.
Medina-Franco H; Mejía-Fernández L
Chin Clin Oncol; 2018 Dec; 7(6):57. PubMed ID: 30180749
[TBL] [Abstract][Full Text] [Related]
56. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
57. Regarding "When Less Is More: Minimally Invasive Surgery Compared to Laparotomy for Interval Debulking after Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer".
Bogani G; Ditto A; Raspagliesi F
J Minim Invasive Gynecol; 2019; 26(3):573-574. PubMed ID: 30503756
[No Abstract] [Full Text] [Related]
58. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer.
Park JY; Heo EJ; Lee JW; Lee YY; Kim TJ; Kim BG; Bae DS
J Gynecol Oncol; 2016 Mar; 27(2):e20. PubMed ID: 26768783
[TBL] [Abstract][Full Text] [Related]
60. Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study.
Rafii A; Deval B; Geay JF; Chopin N; Paoletti X; Paraiso D; Pujade-Lauraine E
Int J Gynecol Cancer; 2007; 17(4):777-83. PubMed ID: 17367318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
